Effect of Oral Glucosamine on glucose and insulin levels in patients with osteoarthritis

Effect of Oral Glucosamine on blood glucose and insulin level in patients with osteoarthritis during glucose tolerance test

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201304284167N5

Enrollment

Registered

2014-05-08

Start date

2012-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis. Polyarthrosis, unspecified

Interventions

Intervention 1: Intervention group: Glucosamine 1500 mg daily until three months. Intervention 2: Control group: One placebo tablet daily till 3 months.

Treatment - Drugs

Placebo

Intervention group: Glucosamine 1500 mg daily until three months

Control group: One placebo tablet daily till 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Osteoarthritis non diabetic patients with American College Of Rheumatology criteria for diagnosis of osteoarthritis of hand, knee and or hip; patients who complete the consent form and participate to study consciously. Exclusion criteria: Having body mass index lower than 20 and or higher than 30, history of diabetes or fast blood sugar upper than 110; history of liver or renal disease, myocardial infarction, uncontrolled inflammatory diseases, malignancy and endocrine disorder which interfere glucose metabolism; consumption of corticosteroids and other effective medicine on blood glucose; anemia; pregnancy or lactation

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: Baseline and after 3 months intervention. Method of measurement: Glucose oxidase Method.;Glucose tolerance test. Timepoint: Baseline and after 3 months intervention. Method of measurement: Glucose oxidase Method.;Fasting insulin serum. Timepoint: Baseline and after 3 months intervention. Method of measurement: Immunoradiometric assay.	—

Secondary

Measure	Time frame
Insulin Resistance. Timepoint: Baseline and after 3 months intervention. Method of measurement: HOMA-IR index.;Fasting insulin serum. Timepoint: Baseline and after 3 months intervention. Method of measurement: Immunoradiometric assay.;Fasting blood glucose. Timepoint: Baseline and after 3 months intervention. Method of measurement: Glucose oxidase Method.;Glucose tolerance test. Timepoint: Baseline and after 3 months intervention. Method of measurement: Glucose oxidase Method.	—

Measure

Time frame

Insulin Resistance. Timepoint: Baseline and after 3 months intervention. Method of measurement: HOMA-IR index.;Fasting insulin serum. Timepoint: Baseline and after 3 months intervention. Method of measurement: Immunoradiometric assay.;Fasting blood glucose. Timepoint: Baseline and after 3 months intervention. Method of measurement: Glucose oxidase Method.;Glucose tolerance test. Timepoint: Baseline and after 3 months intervention. Method of measurement: Glucose oxidase Method.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactShokoufeh Bonakdaran

Mashhad University of Medical Sciences

bonakdaransh@mums.ac.ir+98 51 1801 2976

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026